留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

根除幽门螺杆菌四联疗法对胃肠道微生态的影响

姚敏 李艳梅

姚敏, 李艳梅. 根除幽门螺杆菌四联疗法对胃肠道微生态的影响[J]. 协和医学杂志, 2019, 10(3): 268-271. doi: 10.3969/j.issn.1674-9081.2019.03.014
引用本文: 姚敏, 李艳梅. 根除幽门螺杆菌四联疗法对胃肠道微生态的影响[J]. 协和医学杂志, 2019, 10(3): 268-271. doi: 10.3969/j.issn.1674-9081.2019.03.014
Min YAO, Yan-mei LI. Effect of the Quadruple Therapy of Eradicating Helicobacter Pylori on Gastrointestinal Microecology[J]. Medical Journal of Peking Union Medical College Hospital, 2019, 10(3): 268-271. doi: 10.3969/j.issn.1674-9081.2019.03.014
Citation: Min YAO, Yan-mei LI. Effect of the Quadruple Therapy of Eradicating Helicobacter Pylori on Gastrointestinal Microecology[J]. Medical Journal of Peking Union Medical College Hospital, 2019, 10(3): 268-271. doi: 10.3969/j.issn.1674-9081.2019.03.014

根除幽门螺杆菌四联疗法对胃肠道微生态的影响

doi: 10.3969/j.issn.1674-9081.2019.03.014
详细信息
    通讯作者:

    李艳梅 电话:0471-3451755, E-mail:nmgliyanmei@163.com

  • 中图分类号: R516;R453.2

Effect of the Quadruple Therapy of Eradicating Helicobacter Pylori on Gastrointestinal Microecology

More Information
  • 摘要: 幽门螺杆菌(Helicobacter plyori, Hp)的感染及治疗是全球普遍关注的热点问题。近年来全球多数地区Hp耐药性增加且根除率下降。目前根除Hp的一线疗法为四联疗法, 使用的抗生素比三联疗法剂量更大、疗程更长, 这会造成胃肠道菌群失调, 胃肠道微生态系统的组成发生改变, 优势菌群减少, 甚至导致小肠细菌过度生长、艰难梭菌的定植等。上述改变很可能与在根除Hp过程中产生的不良反应及根除后感染复发有关。
    利益冲突  无
  • [1] Martin ME, Solnick JV. The gastric microbial community, Helicobacter pylori colonization, and disease[J]. Gut Microbes, 2014, 5:345-350. doi:  10.4161/gmic.28573
    [2] 刘文忠. 《幽门螺杆菌感染的处理:Maastricht Ⅴ/Florence共识报告》解读[J].胃肠病学, 2016, 21:577-584. doi:  10.3969/j.issn.1008-7125.2016.10.001
    [3] Hunt RH, Camilleri M, Crowe SE, et al. The stomach in health and disease[J]. Gut, 2015, 64:1650-1668. doi:  10.1136/gutjnl-2014-307595
    [4] 高杰, 林倩云, 彭文玲, 等.幽门螺杆菌和胃微生态系统与胃疾病的关系[J].中华消化杂志, 2017, 37:205-208. doi:  10.3760/cma.j.issn.0254-1432.2017.03.018
    [5] 何桂珍.肠道屏障功能与细菌移位[J].协和医学杂志, 2012, 3:260-264. doi:  10.3969/j.issn.1674-9081.2012.03.003
    [6] Zhernakova A, Kurilshikov A, Bonder MJ, et al. Popula-tion-based metagenomics analysis reveals markers for gut microbiome composition and diversity[J]. Science, 2016, 352:565-569. doi:  10.1126/science.aad3369
    [7] 潘飞, 任荣荣, 杨云生, 等.肠道微生态与结直肠癌关系的研究进展[J].循证医学, 2017, 17:120-124. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=xzyx201702013
    [8] 于阿莉, 刘响, 安莹莹, 等.肠道菌群失调与慢性便秘的研究进展[J].国际消化病杂志, 2017, 37:83-86. doi:  10.3969/j.issn.1673-534X.2017.02.005
    [9] Hartstra AV, Bouter KE, Bäckhed F, et al. Insights into the role of the microbiome in obesity and type 2 diabetes[J]. Diabetes Care, 2015, 38:159, 165. http://med.wanfangdata.com.cn/Paper/Detail/PeriodicalPaper_PM25538312
    [10] Yin YN, Wang CL, Liu XW, et al. Gastric and duodenum microflora analysis after long-term Helicobacter pylori infection in Mongolian Gerbils[J].Helicobacter, 2011, 16:389-397. doi:  10.1111/j.1523-5378.2011.00862.x
    [11] Mi JK, Kim H. Anticancer Effect of Lycopene in Gastric Carcinogenesis[J]. J Cancer Prev, 2015, 20:92-96. doi:  10.15430/JCP.2015.20.2.92
    [12] Avilesjimenez F, Vazquezjimenez F, Medranoguzman R, et al. Stomach microbiota composition varies between patients with non-atrophic gastritis and patients with intestinal type of gastric cancer[J]. Sci Rep, 2014, 4:4202. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3935187/
    [13] Wang L, Zhou J, Xin Y, et al. Bacterial overgrowth and diversification of microbiota in gastric cancer[J]. Eur J Gastroenterol Hepatol, 2016, 28:261-266. doi:  10.1097/MEG.0000000000000542
    [14] Dore MP, Cipolli A, Ruggiu MW, et al. Helicobacter pylori eradication may influence timing of endoscopic surveillance for gastric cancer in patients with gastric precancerous lesions:A retrospective study[J]. Medicine, 2018, 7:e9734. http://europepmc.org/article/PMC/5794400
    [15] Khosravi Y, Seow SW, Amoyo AA, et al. Helicobacter pylori infection can affect energy modulating hormones and body weight in germ free mice[J]. Scientific Reports, 2015:8731. https://pubmed.ncbi.nlm.nih.gov/25736205/
    [16] Lebwohl B, Spechler SJ, Wang TC, et al. Use of proton pump inhibitors and subsequent risk of celiac disease[J].Dig Liver Dis, 2014, 46:36-40. doi:  10.1016/j.dld.2013.08.128
    [17] Castaño-Rodríguez N, Kaakoush NO, Lee WS, et al. Dual role of Helicobacter and Campylobacter species in IBD:a systematic review and meta-analysis[J]. Gut, 2017, 66:235-249. doi:  10.1136/gutjnl-2015-310545
    [18] Zhang YX, Zhou LY, Song ZQ, et al. Primary antibiotic resistance of Helicobacter pylori strains isolated from patients with dyspeptic symptoms in Beijing:a prospective serial study[J]. World J Gastroenterol, 2015, 21:2786-2792. doi:  10.3748/wjg.v21.i9.2786
    [19] 中华医学会消化病学分会幽门螺杆菌学组/全国幽门螺杆菌科研协作组成虹, 胡伏莲, 谢勇, 等.中国幽门螺杆菌耐药状况以及耐药对治疗的影响——全国多中心临床研究[J].胃肠病学, 2007, 12:525-530. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=wcbx200709005
    [20] Jakobsson HE, Jernberg C, Ersson AF, et al. Short-term antibiotic treatment has differing long-term impacts on the human throat and gut microbiome[J]. PLoS One, 2010, 5:e9836. doi:  10.1371/journal.pone.0009836
    [21] Iizumi T, Battaglia T, Ruiz V, et al. Gut Microbiome and Antibiotics[J]. Arch Med Res, 2017, 48:727-734. doi:  10.1016/j.arcmed.2017.11.004
    [22] Sugimoto M, Furuta T. Efficacy of tailored Helicobacter pylori eradication therapy based on antibiotic susceptibility and CYP2C19 genotype[J]. World J Gastroenterol, 2014, 20:6400-6411. doi:  10.3748/wjg.v20.i21.6400
    [23] Lo WK, Chan WW. Proton pump inhibitor use and the risk of small intestinal bacterial overgrowth:a meta-analysis[J]. Clin Gastroenterol Hepatol, 2013, 11:483-490. doi:  10.1016/j.cgh.2012.12.011
    [24] Trifan A, Stanciu C, Girleanu I, et al. Proton pump inhibitors therapy and risk of Clostridium difficile infection:Systematic review and meta-analysis[J]. World J Gastroenterol, 2017, 23:6500-6515. doi:  10.3748/wjg.v23.i35.6500
    [25] Jackson MA, Goodrich JK, Maxan ME, et al. Original article:Proton pump inhibitors alter the composition of the gut microbiota[J]. Gut, 2016, 65:749-756. doi:  10.1136/gutjnl-2015-310861
    [26] Dore MP, Lu H, Graham DY. Role of bismuth in improving Helicobacter pylori eradication with triple therapy[J]. Gut, 2016, 65:870-878. doi:  10.1136/gutjnl-2015-311019
    [27] Tahir S, Fallone CA. Effectiveness of Second through Sixth Line Salvage Helicobacter pylori Treatment:Bismuth Quadruple Therapy is Almost Always a Reasonable Choice[J]. Can J Gastroenterol Hepatol, 2016, (2):7321574. https://pubmed.ncbi.nlm.nih.gov/26523455/
  • 加载中
计量
  • 文章访问数:  246
  • HTML全文浏览量:  25
  • PDF下载量:  26
  • 被引次数: 0
出版历程
  • 收稿日期:  2018-06-12
  • 刊出日期:  2020-09-18

目录

    /

    返回文章
    返回

    【温馨提醒】近日,《协和医学杂志》编辑部接到作者反映,有多名不法人员冒充期刊编辑发送见刊通知,鼓动作者添加微信,从而骗取版面费的行为。特提醒您,本刊与作者联系的方式均为邮件通知或电话,稿件进度通知邮箱为:mjpumch@126.com,编辑部电话为:010-69154261,请提高警惕,谨防上当受骗!如有任何疑问,请致电编辑部核实。谢谢!